www.ciloa.fr Open in urlscan Pro
213.186.33.17  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.ciloa.fr/

<form class="w-form-row for_text" action="https://www.ciloa.fr/" method="get">
  <div class="w-form-row-field"><input type="text" name="s" placeholder="Search" aria-label="Search" value=""></div><button aria-label="Close" class="w-search-close" type="button"></button>
</form>

Text Content

search

 * COMPANY
   * MISSIONS
   * HISTORY
   * MANAGEMENT
   * PARTNERS
 * TECHNOLOGY
   * MEMBRANE PROTEINS
   * EXOSOMES
   * CILOA TECHNOLOGY
   * ADDED VALUE
 * APPLICATION FIELDS
   * ANTIBODIES
   * VACCINES
   * THERAPEUTIC VECTORS
 * WORKING WITH US
 * NEWS
 * CONTACT
   * CAREERS
 * 



Skip
D
R
U
G
T
H
E
U
N
D
R
U
G
G
A
B
L
E
w
i
t
h
C
i
l
o
a
'
s
r
e
c
o
m
b
i
n
a
n
t
e
x
o
s
o
m
e
s
ANTIBODIES Against challenging antigens VACCINES Virus and Adjuvant Free
THERAPEUTIC VECTORS Virus Free WORKING TOGETHER to develop new high potential
therapies

NATIVE MEMBRANE PROTEIN COMPLEXES GPCRs, kinase receptors, ion channels... ON
EXOSOMES OUT OF CELLS


FULLY NATIVE MEMBRANE PROTEINS ON EXOSOMES
TO OVERCOME UNDRUGGABLE TARGETS

Ciloa is dedicated to the development of new high potential therapies. It was
built on more than 15 years of research on bio-drug development technology using
exosomes.

Ciloa’s technology allows to address oncology, infectiology, cardiology, genetic
and neurological diseases, and more.

Our technology is the only one allowing to produce all types of membrane
proteins with their native conformation on exosomes. It allows to load exosomes
with cytosolic proteins as well. It thus makes it possible to reach the most
difficult families of membrane protein targets, known as “undruggable”, some
being the most promising for therapies.

Ciloa takes advantage of the natural properties of exosomes; they are natural
immuno-stimulators, biocompatible, intercellular membrane messengers, and able
to cross all the human body barriers including the blood-brain barrier.

MORE ABOUT CILOA


COMPANY

Ciloa exosomes offer a disruptive way to develop a new generation of
high-potential therapies.


TECHNOLOGY

Our unique technology allow to produce any type of membrane protein (including
GPCR and more.) with their fully native conformation on exosomes outside the
cell.


APPLICATIONS

Therapeutic and preventive vaccines, monoclonal antibodies, immunotherapies, and
therapeutic vectors carrying drug cargo


WORKING WITH US

Ciloa is uniquely positioned to support your scientific project with membrane
proteins on exosomes and close partnerships with academic technology platforms
and dedicated biotech structures.

LATEST NEWS



CILOA @ISEV 2022 FROM 25 TO 29 MAY (LYON, FRANCE)

12 May 2022
Ciloa’s team will  be pleased to present its last progress on extracellular
vesicle (EV) editing and production. Come visit us…
Read More


CILOA SECURES €5 MILLION FOR BIOMEDICINES AND VACCINES DEVELOPMENT

8 March 2022
Ciloa secures €5 million for the development of its new generation of
biomedicines and vaccines using exosomes The company finalized…
Read More


CILOA @FRANCE BIOPRODUCTION 2021

14 June 2021
Ciloa is pleased to be a partner of the 5th edition of the France Bioproduction
congress. Meet Robert Mamoun, Philippe…
Read More


CILOA @VIVATECH 2021

11 June 2021
Ciloa is pleased to join its partner Sanofi at the Viva Technology Conference
2021, the world’s rendezvous for startups and leaders…
Read More

Read more news
Twitter
LinkedIn
YouTube
RSS

© Ciloa all rights reserved

Legal

Menu